Fact CheckerSign in

NCT07189377RecruitingPhase 4

Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors

Lung Transplantation Using Hepatitis B Positive Donors to Hepatitis B Negative Recipients Using Ex-Vivo Treatment of Organs: A Safety Trial

Source: ClinicalTrials.gov · Last updated 17 Nov 2025

Brief summary (registry, in English)

The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals

Status (registry)
Recruiting
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
20 (estimated)
First submitted
9 Sept 2025
Start date
24 Sept 2025
Primary completion date
31 Aug 2027
Lead sponsor
University Health Network, Toronto
Diseases
Hepatitis B
NCT number
NCT07189377

What you commit to

  • Study type: Interventional · Phase 4
  • Planned participants: 20
  • From 24 Sept 2025 to the primary completion date, 31 Aug 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • Donor Inclusion Criteria
  • Donor lung suitable for transplantation
  • HBV SAg positive and/or HBV NAT+ donor
    • Donor Exclusion Criteria
  • HIV positive
  • HTLV 1/2 positive;
  • Any medical issues in the donor that would normally clinically exclude the donor (e.g. history of cancer, evidence of organ dysfunction, etc).
    • Recipient inclusion Criteria:
  • Recipients eligible and listed for lung transplant
  • HBV NAT negative
  • Provides written informed consent
  • Has received at least 3 prior doses of Hepatitis B vaccine or anti-HBs\>=10 IU/mL
  • Patients with other co-morbid conditions (such as diabetes, autoimmune disease, renal dysfunction) will remain eligible provided they are otherwise medically suitable for transplantation. The exception to this will be patients with significant liver disease as outlined below.
    • Recipient exclusion Criteria:
  • Chronic liver disease with \> stage 2 fibrosis
  • Participating in another interventional clinical trial
  • Recipient listed for combined transplant (e.g., heart-lung, lung-liver)
  • Known allergy or contraindication to any of the antiviral medications
  • Hepatitis B surface antigen (HBsAg) or Hepatitis B core Ab positive pre-transplant (indicates already HBV infected).
  • HIV positive
  • Patients with a low level of serum IgA pre-transplant (this may be a risk factor for sensitivity reaction to HBIG).

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University Health Network, Toronto General Hospital
Coordinator of this site? Confirm its status
TorontoCanadaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.